Prognostic Significance of The Nadir Prostate Specific Antigen Level After Hormone Therapy for Prostate Cancer-Reference-Cited by-同舟云学术

Prognostic Significance of The Nadir Prostate Specific Antigen Level After Hormone Therapy for Prostate Cancer

Published:2002-09 Issue:3 Volume:168 Page:995-1000
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Kwak Cheol¹,Jeong Seong Jin¹,Park Moon Soo¹,Lee Eunsik¹,Lee Sang Eun¹

Affiliation:

1. From the Department of Urology, Seoul National University College of Medicine and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference15 articles.

1. Goserelin acetate flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853).EORTC GU Group EORTC Data Center;Denis;Urology,1993

2. Value of biochemical markers in the management of disseminated prostatic cancer;Mulders;Eur Urol,1992

3. Prostate specific antigen prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate;Dupont;J Urol,1991

4. Elevated plasma chromogranin-A concentrations in prostatic carcinoma;Kadmon;J Urol,1991

5. Hormone therapy in prostate cancer;Whitmore;Am J Med,1956

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy;Journal of Cancer Research and Therapeutics;2023-12-15

2. The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [68Ga]Ga-PSMA-11-PET/CT in high-risk prostate cancer patients treated with definitive radiotherapy;European Journal of Nuclear Medicine and Molecular Imaging;2023-07-05

3. The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients;Radiotherapy and Oncology;2023-07

4. Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer;BMC Cancer;2023-06-20

5. Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the J‐ROCK study;International Journal of Urology;2022-08-26